Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

155
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
155
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.5K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corneal Innervation Research at a Crossroads: A Tool-Driven Roadmap for the Future.

Investigative ophthalmology & visual science·2026
Same author

Culture-proven endophthalmitis associated with Boston Type I keratoprosthesis: clinical features, microbiologic aspects, and outcomes.

Journal of ophthalmic inflammation and infection·2026
Same author

Robust registration under large image misalignment using an iterative step-aware transformer with application to corneal confocal microscopy.

Biomedical optics express·2026
Same author

Corrigendum to "TFOS DEWS III: Digest" Am J Ophthalmol. 2025; 279:451-553.

American journal of ophthalmology·2026
Same author

Clinical Features and Treatment Outcomes of Patients with Tubulointerstitial Nephritis and Uveitis Syndrome: A Case Series.

Ocular immunology and inflammation·2026
Same author

TFOS DEWS III.

American journal of ophthalmology·2025

Related Experiment Video

Updated: Mar 15, 2026

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

1.1K

Emerging therapeutics for ocular surface disease.

Brett P Bielory1, Steven P Shah, Terrence P O'Brien

  • 1aThomas Jefferson University Kimmel School of Medicine, Philadelphia, PennsylvaniabRutgers University, Center for Environmental Prediction, New BrunswickcUniversity Asthma and Allergy Associates, STARx Asthma and Allergy Center, Springfield, New JerseydDepartment of Ophthalmology, New York Medical College, Valhalla, New YorkeBascom Palmer Eye Institute at Palm Beach Gardens, Palm Beach GardensfBascom Palmer Eye Institute, Miami, Florida, USA.

Current Opinion in Allergy and Clinical Immunology
|September 2, 2016
PubMed
Summary

New treatments targeting immune pathways show promise for chronic ocular allergy and dry eye disorder (DED). Understanding immunopathophysiology offers novel therapeutic strategies for these common ocular surface conditions.

More Related Videos

Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases
07:36

Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases

Published on: July 3, 2025

858
Induction of Ocular Surface Inflammation and Collection of Involved Tissues
06:38

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

3.0K

Related Experiment Videos

Last Updated: Mar 15, 2026

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

1.1K
Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases
07:36

Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases

Published on: July 3, 2025

858
Induction of Ocular Surface Inflammation and Collection of Involved Tissues
06:38

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

3.0K

Area of Science:

  • Ophthalmology and Immunology
  • Ocular Surface Disease Research

Background:

  • Chronic ocular allergy and dry eye disorder (DED) are common, yet frequently underdiagnosed and undertreated.
  • Limited therapeutic options necessitate the search for alternative treatments for these inflammatory ocular surface conditions.

Purpose of the Study:

  • To review current systemic and topical treatments for chronic ocular allergy and DED.
  • To explore novel therapeutic targets and strategies based on recent advances in immunopathophysiology.

Main Methods:

  • Review of current literature on ocular allergy and DED treatments.
  • Analysis of recent findings in the immunopathophysiology of ocular surface disorders.

Main Results:

  • Advances in understanding immune pathways (Th1/Th2) offer new therapeutic targets.
  • Potential novel treatments include immunobiological modulators targeting cytokines (IL-1, IL-4, IL-5, IL-13) and IgE.
  • Emerging therapies include topical glucocorticoids, leukotriene receptor antagonists, and IL-1, IL-5, IL-4/IL-13, and integrin antagonists.

Conclusions:

  • Novel immunomodulatory approaches hold significant potential for managing ocular allergy and DED.
  • A deeper understanding of molecular and cellular mechanisms is paving the way for innovative treatments for anterior surface ocular disorders.